ITI MF

CATEGORY OF SCHEME	Sectoral/Thematic
INVESTMENT OBJECTIVE	The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Inception Date (Date of Allotment):	08-Nov-21
Benchmark:	Nifty Healthcare TRI
Minimum Application Amount:	Rs.5,000/- and in multiples of Rs. 1/- thereafter
Load Structure:	Entry Load: Nil Exit Load: 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units · Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.
Total Expense Ratio (TER):	Including Additional Expenses and Goods and Service Tax on Management Fees Regular Plan: 2.25% Direct Plan: 0.37%
Fund Manager	Mr. Rohan Korde (Since 08-Nov-21) Total Experience: 17 years Mr. Dhimant Shah (Since 01 December 2022) Total Experience : 26 years

AUM (in Rs. Cr):	216.51
AAUM (in Rs. Cr):	223.27
% of top 5 holdings:	37.14%
% of top 10 holdings:	56.12%
No. of scrips:	37

Standard Deviation^:	15.67%
Beta^:	0.91
*Sharpe Ratio^:**	0.72
Average P/B	8.78
Average P/E	46.65
Portfolio Turnover Ratio	0.64
^Computed for the 3-yr period ended January 31, 2025. Based on monthly return. * Risk free rate: 6.65 (Source: FIMMDA MIBOR)

	Regular Plan (in Rs.)	Direct Plan (in Rs.)
Growth:	15.8617	16.9514
IDCW:	15.8617	16.9514

Name of the Instrument	% to NAV	% to NAV Derivatives
Equity & Equity Related Total	93.44
Chemicals	2.82
Sumitomo Chemical India Limited	1.37
SRF Limited	0.74
Linde India Limited	0.71
Healthcare	90.62
Sun Pharmaceutical Industries Limited	16.00
Lupin Limited	6.34
Apollo Hospitals Enterprise Limited	5.03
Divi's Laboratories Limited	4.89
Suven Pharmaceuticals Limited	4.88
Aurobindo Pharma Limited	4.78
Max Healthcare Institute Limited	4.05
Torrent Pharmaceuticals Limited	3.85
Dr. Reddy's Laboratories Limited	3.39
Alkem Laboratories Limited	2.91
Aster DM Healthcare Limited	2.52
Mankind Pharma Limited	2.42
Granules India Limited	2.15
Syngene International Limited	1.88
Neuland Laboratories Limited	1.86
Orchid Pharma Limited	1.84
Wockhardt Limited	1.80
Healthcare Global Enterprises Limited	1.61
Caplin Point Laboratories Limited	1.41
Fortis Healthcare Limited	1.41
FDC Limited	1.40
Shilpa Medicare Limited	1.34
Supriya Lifescience Limited	1.33
Emcure Pharmaceuticals Limited	1.27
Vijaya Diagnostic Centre Limited	1.21
Gland Pharma Limited	1.16
Yatharth Hospital And Trauma Care Services Limited	1.13
Rainbow Childrens Medicare Limited	1.06
Cipla Limited	1.05
Onesource Specialty Pharma Limited	1.01
GlaxoSmithKline Pharmaceuticals Limited	0.94
Sequent Scientific Limited	0.93
Sai Life Sciences Limited	0.90
Strides Pharma Science Limited	0.87
Short Term Debt & Net Current Assets	6.56

Top Ten Holdings

Period	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Benchmark (Rs)	Fund (Rs)	Additional Benchmark Returns (Rs)
Regular - Growth
Last 1 Year	21.79%	21.38%	9.55%	12,186	12,144	10,958
Last 3 Years	17.86%	19.58%	12.01%	16,379	17,106	14,058
Since Inception	15.34%	16.35%	9.74%	15,862	16,316	13,506
Direct - Growth
Last 1 Year	24.10%	21.38%	9.55%	12,417	12,144	10,958
Last 3 Years	20.29%	19.58%	12.01%	17,413	17,106	14,058
Since Inception	17.73%	16.35%	9.74%	16,951	16,316	13,506

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. In case, the start / end date of the concerned period is a non-business date (NBD), the NAV of the previous date is considered for computation of returns. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Rohan Korde (Managing since 08-Nov-21) and Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021). Face Value per unit: Rs. 10. Since the scheme is in existence for more than 3 years but less than 5 years hence performance data for 5 years and more are not provided.
ITI Pharma & Healthcare Fund NAV as on January 31, 2025: Rs. 15.8617 (Regular Growth Option), Rs. 16.9514 (Direct Growth Option)

Period	Amount Invested	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Fund Value ()	Benchmark Value ()	Additional Benchmark Value ()
Regular - Growth
Last 1 Year	1,20,000	11.28%	10.76%	0.02%	1,27,203	1,26,874	1,20,014
Last 3 Years	3,60,000	25.08%	25.87%	13.37%	5,18,091	5,23,682	4,39,534
Since Inception	3,90,000	23.52%	24.28%	12.97%	5,65,630	5,72,095	4,81,082
Direct - Growth
Last 1 Year	1,20,000	13.46%	10.76%	0.02%	1,28,569	1,26,874	1,20,014
Last3 Years	3,60,000	27.55%	25.87%	13.37%	5,35,826	5,23,682	4,39,534
Since Inception	3,90,000	25.96%	24.28%	12.97%	5,86,546	5,72,095	4,81,082

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).